AstraZeneca considers moving listing to US, the Times reports

AstraZeneca, London's most valuable company with a £156 billion market capitalization, is reportedly considering moving its primary stock market listing to the United States, a shift privately favored by CEO Pascal Soriot. This potential relocation, driven by the company's long-standing criticism of the UK business climate and its significant $3.5 billion US manufacturing investments coupled with the US being its largest market (42% of Q1 revenue), would be a substantial blow to the London exchange. While its London-listed shares rose 2.8% on the news, the strategic move could face opposition from some board members and the UK government.

Analysis

AstraZeneca, the London Stock Exchange's most valuable company with a market capitalization of approximately £156 billion, is reportedly considering a primary stock listing relocation to the United States. This potential strategic shift is reportedly favored by CEO Pascal Soriot and is underpinned by the company's long-standing criticism of the UK's business investment climate, exemplified by its decision in January to cancel a £450 million investment in a UK vaccine plant due to cuts in government support. The move aligns with a deepening commitment to the US, which is already its largest market, accounting for 42% of Q1 revenue. This commitment is further evidenced by a planned $3.5 billion investment in US manufacturing by 2026 and the company's recent rejoining of the primary US drug lobby. The market has reacted positively to the news, with London-listed shares climbing 2.8%, suggesting investors anticipate a valuation uplift from accessing deeper US capital markets. However, the move faces significant hurdles, including potential opposition from board members and the UK government, as well as geopolitical uncertainty stemming from a threatened 25% US tariff on pharmaceutical imports.

Key Decisions for Investors

• Investors should monitor for any official company announcement, as the current report is unconfirmed and a formal review would be the primary catalyst for re-evaluating the stock's long-term value.
• The 2.8% share price increase indicates a perceived valuation arbitrage, but this potential upside must be weighed against significant execution and political risks, including dissent from the board or the UK government.
• Given the company's growing US revenue concentration and manufacturing footprint, it is critical to assess the potential impact of US trade policy, particularly the threatened 25% pharmaceutical tariff, on future profitability.